Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | GLS | O94925 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207902 | 0.85 | MTNR1B (0.40) | NQO2GLSPTGESAKT1CA12 | |
| SCHEMBL4846611 | 0.84 | PTGES (0.38) | HDAC1HDAC3HDAC2NCOR2NQO2 | |
| SCHEMBL29850324 | 0.82 | NQO2 (0.43) | NQO2GLSPTGESSYK | |
| SCHEMBL29597551 | 0.79 | AKT1 (0.39) | AKT1CA12CA1CA7CA14 | |
| SCHEMBL6366961 | 0.78 | MAPT (0.36) | HDAC1HDAC3HDAC2NQO2PTGES | |
| SCHEMBL207886 | 0.77 | PTGES (0.36) | HDAC1HDAC3HDAC2NCOR2NQO2 | |
| SCHEMBL207899 | 0.77 | LCK (0.32) | NQO2GLSPTGESAKT1CA12 | |
| SCHEMBL29850447 | 0.76 | PTGES (0.36) | NQO2GLSPTGESCTSS | |
| SCHEMBL17894519 | 0.75 | MIF (0.42) | NQO2AKT1CTSS | |
| SCHEMBL6701851 | 0.75 | MAPT (0.49) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088941-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2012-01-03 | — | — | US | disclosed |
| US-20080312188-A1 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-12-18 | — | — | US | disclosed |
| US-7378432-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-05-27 | — | — | US | disclosed |
| EP-1638557-A4 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | UNIV TEL AVIV FUTURE TECH DEV (IL) | 2007-11-07 | — | — | EP | disclosed |
| US-20060069066-A1 | 3-(4-(3-guanidinophenyl)-1,2,3-triazol-1-yl)benzyl phosphoric acid hydrochloride; obesity, non-insulin dependent diabetes mellitus, insulin-dependent condition, affective disorder, neurodegenerative diseases, psychotic disease; compounds having hydrophobic moiety to a terminus of a peptide GSK-3 | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. | 2006-03-30 | — | — | US | disclosed |
| EP-1638557-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Tel Aviv University Future Technology Development L.P. (IL) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000192-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069066-A1 | 3-(4-(3-guanidinophenyl)-1,2,3-triazol-1-yl)benzyl phosphoric acid hydrochloride; obesity, non-insulin dependent diabetes mellitus, insulin-dependent condition, affective disorder, neurodegenerative diseases, psychotic disease; compounds having hydrophobic moiety to a terminus of a peptide GSK-3 | GSK3A, GSK3B, PYGB | HDAC1 1184/4885HDAC3 212/4885HDAC2 2025/4885 |
| US-20080312188-A1 | Glycogen synthase kinase-3 inhibitors | GSK3B, GSK3A, GSKIP | HDAC1 1470/4885HDAC3 582/4885HDAC2 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.